The 19q13 amplicon in pancreatic cancer cells contains a novel pancreatic differentiation 2 (PD2) gene (accession number AJ401156), which was identified by differential screening analysis. PD2 is the human homologue of the RNA polymerase II-associated factor 1 (hPaf1). In yeast, Paf1 is part of the transcription machinery, acting as a docking protein in between the complexes Rad6-Bre1, COMPASS-Dot1p, and the phosphorylated carboxyl terminal domain of the RNA polymerase II. As such, Paf1 is directly involved in transcription elongation via histone H2B ubiquitination and histone H3 methylation. The PD2 sequence is highly conserved from Drosophila to humans with up to 98% identity between rodent and human, suggesting the functional importance of PD2/ hPaf1 to maintain cellular homeostasis. PD2 is a modular protein composed of RNA recognition motif, DEADboxes, an aspartic/serine (DS)-domain, a regulator of the chromosome condensation domain and myc-type helixloop-helix domains. Our results further showed that PD2 is a nuclear 80 kDa protein, which interacts with RNA polymerase II. In addition, we have demonstrated that the overexpression of PD2 in the NIH 3T3 cells result in enhanced growth rates in vitro and tumor formation in vivo. Altogether, this paper presents strong evidence that the overexpression of PD2/hPaf1 is involved in cancer development.
Introduction
The accumulation of genetic alterations in somatic cells, such as mutations, changes in the number of chromosomes, chromosomal translocations, and gene amplifications, induce a transformed phenotype leading to cancer. These genetic alterations constitute key events contributing to tumor progression and metastasis. They are often stabilized when they confer a growth or survival advantage to the cells (Lengauer et al., 1998) .
Gene amplification (HSR, homogeneously staining region and DM, double minute) is one of the most important mechanisms leading to the alteration of gene expression in solid tumors. The best example studied is the amplification of HER2 on the chromosomal locus 17q12 in primary breast cancer. HER2 is named for human epidermal growth factor receptor-2 and belongs to the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases (RTKs). In total, 25-30% of women with breast cancer demonstrate amplification and overexpression of the HER2 gene (Slamon et al., 1987) . Amplification/overexpression of HER2 induces the phosphorylation of p27
Kip (inhibitor of the cdk2) on threonine 157 by AKT and its retention in the cytoplasm (Blain and Massague, 2002; Shin et al., 2002) , leading the cells to enter the cell cycle and proliferate.
Amplicons often contain several syntenic genes, such as an amplification of the 11q13 locus that encompasses FGF3, FGF4, and CYCD1 (Gaudray et al., 1992) or the amplification of the locus 12q13 that encompasses MDM2, CDK4, and GLI (Khatib et al., 1993) . We now recognize that amplicons are stabilized in the human genome when they encompass several genes that provide a selective growth advantage to the cell. In some cases, the stabilization of an amplicon is driven by amplification of nonsyntenic regions such as the coamplification of the loci 12q13 and 2p24 that encompasses MYCN (Khatib et al., 1993) .
Although DNA amplification is found in a wide range of tumor types, recurrent amplification of a particular locus seems limited to specific tumors, such as glioma, breast and ovarian cancers. In an effort to identify differentially expressed genes that may play important roles in pancreatic tumor growth and progression, our laboratory pointed out the existence of a double minute amplification corresponding to the chromosomal locus 19q13 (Batra et al., 1991a, b) . This genomic amplification is now recognized as an underlying cause of many low-frequency genetic events (being amplified in 10-20% of the cases) in pancreatic adenocarcinoma (Griffin et al., 1994; Ruggeri et al., 1998; Altomare et al., 2003) . The 19q13 locus is also amplified in several other cancers such as follicular lymphoma (Werner et al., 1997) , Mantle cell lymphoma (Werner et al., 1997 ), Burkitt's lymphoma, small-cell lung cancer (Ried et al., 1994; Petersen et al., 1997) , non-small-cell lung cancer (Petersen et al., 1997; Bjorkqvist et al., 1998) , breast carcinoma (Kallioniemi et al., 1994) , and uterine cervix cancer (Heselmeyer et al., 1997) .
Two amplified genes have been characterized at the 19q13 locus, including the ribosomal protein, rpS16, and AKT2 (Batra et al., 1991b; Cheng et al., 1996) . AKT2 belongs to a family of three members, AKT1, 2, and 3, which share a strong homology with the PKC and PKA families (Bauer and Baier, 2002) . Activation of AKT2 promotes a variety of biological activities involved in tumorigenesis, such as cell survival and cell-cycle progression. In addition, AKT2 overexpression is reported to be associated with an increase in the aggressiveness of pancreatic cancer cells (Cheng et al., 1996) . For these reasons, AKT2 is considered as the main target gene associated with the 19q13 amplification.
We hypothesized that the stabilization of the 19q13 amplicon, detected in 10-20% of the pancreatic adenocarcinomas, required the presence of another gene favoring tumor development and progression and acting synergistically with AKT2. In the present paper, we describe the identification and characterization of such a novel gene, pancreatic differentiation factor 2 (PD2). We show that the PD2 gene product is the human homologue of the RNA polymerase II-associated factor 1 (hPaf1), a key component of a multifunctional transcriptional complex that is involved in the regulation of gene transcription. The domain-structure of PD2 is conserved in evolution from yeast to human with up to 98% identity between rodent and human. We demonstrate clearly that PD2/hPaf1 possesses transforming activity both in vitro and in vivo.
Results
Identification of the human homologue of yeast Paf1 as part of the 19q13 amplicon To identify markers of differentiation for pancreatic cancer, single-stranded cDNA probes synthesized from both poorly and well-differentiated tumor cells, Panc1 and CD11/HPAF, respectively, were used to screen a lgt11 phage cDNA library of Panc1 cells (Batra et al., 1991a, b) . In total, 17 clones were isolated, subcloned into the pBluescript vector, and sequenced. Among the clones isolated, three were previously reported as the human ribosomal protein S16 (Batra et al., 1991b) , the human ribosomal protein rpL17 (Batra et al., 1991a) , and AKT2 (Cheng et al., 1996) . Another clone from this screening, called PD2, showed an overexpression of approximately 30-fold in Panc1 as compared to CD11/ HPAF (Figure 1 ).
The chromosomal localization of the PD2 gene was determined by screening both the CEPH megabase-insert YAC DNA and the Coriell human X rodent somatic cell hybrid DNA pools. PD2 was mapped to the short arm of chromosome 19 between the q13-qter regions. The NCBI (National Center of Biotechnology Information) human genome resources database was used to resolve its precise location. The PD2 gene was located on chromosome 19 in the q13.2 (loc126275) region, oriented from centromere to telomere, between the IgG binding protein gene (FcGBP) and the zinc-finger protein 36 gene (ZFP36). Interestingly, both PD2 and AKT2 presented the same chromosomal localization, 19q13.2 (Figure 2 ). Since AKT2 is known to be present in an amplicon, we hypothesized that PD2 might be carried on the same chromosomal amplification. Southern blot analysis was performed on Panc1 and CD11/ HPAF cells (Figure 3) , and revealed that Panc1 cells contained a 30-fold gene amplification of PD2 as compared to CD11/HPAF. The ubiquitous expression of PD2/hPaf1 in human, as revealed by blast scan using partial PD2 cDNA sequence, and presence of DNAand RNA-binding domains within its sequence, led us to hypothesize that PD2 might act in concert with AKT2 for the stabilization of the 19q13 amplification.
To validate this hypothesis, we decided to extend and fully characterize the PD2 partial sequence. The PD2 insert was used to screen a lgt11 phage cDNA library P a n c 1 C D 1 1 / H P A F P a n c 1 C D 1 1 / H P A F total RNA poly(A+) RNA PD2 2.4 kb 1.4 kb β-actin Figure 1 Northern blot analysis of PD2 cDNA with RNA from poorly and well-differentiated pancreatic cancer cell lines. Total RNA and purified poly(A) RNA were fractionated by electrophoresis on 1.2% agarose gel containing 0.66 M formaldehyde and transferred onto nitrocellulose via capillary blotting. Lanes 1 and 2 contained total RNA from CD11/HPAF and Panc1, respectively. Lanes 3 and 4 contained poly(A þ ) RNA from CD11/HPAF and Panc1, respectively. The membrane was hybridized with 10 6 cpm/ ml of a-constructed from normal fetal pancreas-derived mRNA. A larger clone (1.9 kb) was isolated, subcloned into the pBluescript vector, and sequenced. The complete PD2 cDNA sequence was submitted to the GenBankt/EBI Data Bank under the accession number, AJ401156. This sequence contained a 5 0 -untranslated region of 156 bp upstream of the ATG translation initiation codon, and was flanked by a Kozak consensus sequence and a 3 0 -untranslated region of 138 bp. The noncoding 3 0 region contained the polyadenylation signal, AATAAA. An open reading frame, from bp 157 to 1752, yields a predicted translation product of 59.9 kDa. A comparison of the genomic sequence (Human Genome Resources Database) with the cDNA sequence provided the genomic structure of PD2 (Figure 4 ). The PD2 gene was 5178-bp long and contained 14 exons of sizes ranging from 30 to 551 bp ( Table 1 ). The first exon contained the 5 0 -untranslated region, the translation start site, and the first 16 amino-acid residues. The last exon contained sequences that coded for a domain rich in serine and aspartic acid residues and the 3 0 -untranslated region. The length and class of each exon and intron are summarized in Table 1 . Introns ranged in size from 78 to 1539 bp. The sequences at the exon/ intron boundaries were highly conserved with respect to canonical acceptor/donor site (AG/GT).
The predicted translation product of the PD2 cDNA was examined for the presence of signature motifs, using PROSITE software at the Expert Protein Analysis System proteomics server of the Swiss Institute of Bioinformation. This analysis revealed a high degree of similarity between PD2 and the functional domains of DNA-and RNA-binding proteins. A schematic representation of the predicted translation product is presented in Figure 4 . A number of domains were identified, including three myc-type helix-loop-helix, a leucine zipper, a DEAD-box subfamily ATP-dependant helicase domain, one eukaryotic RNA recognition motif (RRM) RNP-1 region signature, and a regulator of chromosome condensation (RCC1) signature. Taken together, the presence of these domains suggested that putative functions for the PD2 protein include DNA or RNA binding. Two specific domains were also positioned toward the carboxyl-terminus: a glutamic acidrich domain, from amino acid 358 to 452, and a serine/ aspartic acid-rich domain, from amino acid 402 to 531.
An additional sequence analogy analysis was performed using the database from the NCBI (National Center of Biotechnology Information). This revealed a high degree of similarity between PD2 and sequences from mouse (AK017762, AB041615, BC010317), Drosophila melanogaster (AY070561.1, AC008139, and AE003605), Caenorhabditis elegans (NP_505925, NM_073524 and CAB02869.1), Schizosaccharomyces pombe (CAB65804), and Saccharomyces cerevisiae (P38351). All homologue sequences were compared and aligned as displayed in Figures 4 and 5. The human PD2 showed 98% and 50% similarity to its rodent and Drosophila counterparts, respectively. The S. cerevisiae homologue corresponded to the widely investigated Paf1 protein, which showed 22% identity with the human sequence, and 44% similarity for a segment of 333 amino-acid residues that excluded the carboxyl terminus. Altogether, 22 amino acids were totally conserved among human, rodent, Drosophila, and S. cerevisiae, including two tyrosine residues. The least conserved domain was found in the carboxyl-terminal region. This domain is very rich in serine and aspartic acid residues Human RNA polymerase II-associated factor 1 N Moniaux et al for human PD2, rich in serine and arginine for Drosophila, and absent in the yeast Paf1.
PD2/hPaf1 is a nuclear protein that interacts with RNA polymerase II (RNAPII and DNA) To explore the biological characteristics of PD2, we generated monoclonal antibodies specific for a 22-residue peptide (conjugated to KLH), derived from position 327-348 of PD2. Balb/c mice were immunized with the peptide, and splenocytes from mice producing specific antibodies (following six to seven immunizations) were isolated and fused with the SP2/0 mouse myeloma cell line. Hybridomas were screened for PD2 reactivity by ELISA. The antibody that exhibited the strongest reactivity (F169-3B2) was expanded and used in subsequent experiments.
The subcellular distribution of PD2 in Panc1 and CD11/HPAF cells was investigated using immunoblotting and confocal microscopy. Immunoblotting analyses identified a protein of B80 kDa in the nuclear and total cellular fractions of Panc1, whereas no signal was obtained from the cytoplasmic extract ( Figure 6a ). A similar pattern was also observed for CD11/HPAF cells 
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Upper case, exonic sequence; lower case, intronic sequence; bold underlined letters are 5 0 donor and 3 0 acceptor sites, respectively.
Human RNA polymerase II-associated factor 1 N Moniaux et al ( Figure 6a ). In confocal immunofluorescence microscopy, F169-3B2 strongly reacted to the nuclei of Panc1 cells ( Figure 6c ). The staining presented a punctuate distribution throughout the nuclei except for the nucleoli and the perinuclear chromatin, which remained unlabelled. This pattern of labeling is specific for proteins implicated in the transcriptional process (Grande et al., 1997) . For CD11/HPAF cells, a mild reactivity was detected in the nuclei. To verify that the reactivity of F169-3B2 was truly specific to PD2, this antibody was preincubated with increasing concentrations of the PD2 327-348 peptide before immunoblotting (Figure 6b ). Binding of F169-3B2 to the 80-kDa band was blocked by the PD2 peptide. Likewise, preincubation of F169-3B2 with 1 mg of PD2 peptide also blocked its reactivity in immunofluorescence assays (data not shown). In addition, Panc1 protein extract was pulled down using the F169-3B2 antibody, resolved on 10% acrylamide gel, and immunoblotted with anti-RNA polymerase II rabbit polyclonal (Santa Cruz) antibody. The immunoblot revealed that RNAPII coimmunoprecipitated with PD2 ( Figure 7 ). Two bands migrating at very close molecular weight were detected on the western blot. This result is in accordance with the specificity of the polyclonal anti-RNAPII antibody used in this study that recognizes the tandem repeat domain of the large subunit of the polymerase. The CTD (Carboxyl Terminal Domain) of the RNAPII in mammal is composed by 52 repetitions of the YSPTSPS motif, which is phosphorylated on Ser2 and Ser5. Therefore, PD2 interacts with both Ser2-and Ser5-phosphorylated forms of the RNAPII. PD2 was also detected in the fraction immunoprecipitated using the RNAPII antibody (Figure 7) .
S D E E Q E K G S S S E K E G S E D E H S G S E S E R E E G D R D E A S D K S G S G E D E S S E D E A R A A R D K E E I mouse S D E E Q E K G S S S E K E G S E D E H S G S E S D R E E G D R D E A S D K S G S G E D E S S E D E A R A A R D K E E I drosophila G E T E K T S E D A A V G A Q A A S G A D S P A Q V A R D R Q S R S R S R T R S G S S S G S G S G S G S R A S S R S K S

C. elegans G G D S S D Q S S D S D D D K P Q K S R S D S S S D V S S D D D S P R K K E P T V D S D S D
S. cerevisiae
H R G S D N D S D S G S D G G G Q R S R S Q S R S R S R S A S P F P S G S E H drosophila
G S R S G S G S R S R T N S P A G S Q K S G S R S R S V S R S R S R S K S -G S R S R S R S R S K S G S R S R S G S R S
C. elegans S. cerevisiae
S A Q E D G S E A A A S D S S E A D S D S D mouse S A Q E D G S E A A A S D S S E A D S D S D drosophila G S G S R S P S R S R S G S P S G S G S S S G S A S D E
C. elegans S. cerevisiae pombe Figure 5 Comparison of human PD2 with its mouse, Drosophila, Caenorhabditis elegans, S. pombe, and S. cerevisiae homologues. Identical amino acids are indicated by black letters on a gray background. The KKRK nuclear localization sequence is shown in bold letters.
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The role of PD2 in the transforming phenotype To monitor the oncogenic potential of the PD2 gene, the immortalized NIH 3T3 cells were transfected with the full-length PD2 cDNA in sense and antisense orientations in the pcDNA 3.1 vector. The expression of the PD2 exogene was confirmed by Northern blotting (Figure 8 ) and confocal analyses. The NIH 3T3 PD2 sense-transfected cells presented a four-to five-fold overexpression of PD2 as compared to the NIH 3T3 parental and antisense-transfected cells (Figure 8a ). The level detected in the sense-transfected cells was still far below the level detected in Panc1 cells, resulting from the 19q13 amplification. This result was confirmed by confocal analysis. The NIH 3T3 parental cells presented a mild expression of PD2 while the sense-transfected cells presented a strong expression of the exogene within the nucleus of the cells (Figure 8b ). Using this cellular model, the in vitro effect of PD2 overexpression on growth kinetic was investigated. For this purpose, the cells were seeded at a low density on a six-well plate and expanded for a period of 1 to 8 days. The PD2-sense transfected cells showed faster growth with the doubling time of 18 h as compared to 24 and 22 h in PD2-antisense and control (mock-transfected), respectively ( Figure 8c ). Under an in vivo condition, the PD2-sense transfected cells implanted at the subcutaneous site showed altered growth in vivo compared to the PD2-antisense and the control (mock transfected) cells. The tumors of PD2-sense transfectants showed more tumor volume ( Figure 8d ) and weight ( Figure 8e ) at any given time point. After 20 days post-implantation, the PD2-sense transfected tumors showed a three-fold higher tumor weight and volume over the control and the PD2-antisense transfected cell tumors.
Discussion
The acquisition of the tumor phenotype with the development of macroscopic tumor masses is a multistep process with origin alteration of the genetic milieu. These alterations lead to constitutive activation of oncogenes or inactivation of tumor suppressor genes. The constitutive activation of oncogenes is the result of P a n c 1 N P a n c 1 C P a n c 1 T Interaction between PD2 and RNAPII. The nuclear extract of Panc1 cells was immunoprecipitated with 1 mg/ml of anti-PD2 (F169-3B2) or anti-KLH monoclonal antibodies. Recovered proteins were immunoblotted on 10% SDS-PAGE and incubated with anti-RNAPII rabbit polyclonal antibody C21 (Santa Cruz). A band at a molecular weight above 200 kDa (consistent with the expected molecular weight of RNAPII) was visualized after immunoprecipitation using anti-PD2 antibody (top panel). The same extract was used for immunoprecipitation using the anti-RNAPII antibody or b-globulin. The immunblotting with PD2/ hPAF1 antibody revealed an 80 kDa band (lower panel). As a control for PD2/hPAF1 and RNAPII detection, the crude extracts were run on the same immunoblot (input).
Human RNA polymerase II-associated factor 1 N Moniaux et al chromosomal translocation, amplification, and/or mutation within the gene itself that affects the amino-acid residues regulating the functional activity of the gene product. One example of oncogene activation is the 19q13.2 amplification of the AKT2 gene. AKT2 is reported to be overexpressed in 12.1% of ovarian and 2.8% of breast tumors (Bellacosa et al., 1995) . Amplification or overexpression of AKT2 was especially detected in undifferentiated tumors (Bellacosa et al., 1995) . AKT2, also known as protein Kinase B, is a serine/threonine kinase of 57 kDa (Bellacosa et al., 1991; Jones et al., 1991) . AKT2 is a downstream effector of the PI3-K (phosphatidylinositol 3-kinase) and mediates important cellular mechanisms such as cell survival and inhibition of apoptosis (Datta et al., 1997; Kennedy et al., 1999) . The PI3-K pathway is frequently activated in numerous cancers following amplification or mutation of receptor tyrosine kinases, amplification of PI3-K itself, or its downstream effectors such as AKT2. For these reasons, AKT2 is still known as the main target gene associated with the 19q13 amplification. In addition, overexpression of AKT2 in NIH 3T3 cells presents transforming activity in vitro and in vivo (Cheng et al., 1997) and an increase in the aggressiveness of breast cancer cell lines when implanted in nude mice (Arboleda et al., 2003) .
In the present paper, we emphasize the presence of another gene within the 19q13 amplicon that possesses transforming activity in the NIH 3T3 cells in vitro and in vivo. This gene, first named PD2, was Human RNA polymerase II-associated factor 1 N Moniaux et al further characterized as the human homologue of the yeast RNA polymerase II-associated factor I or hPaf1. The functional importance of hPaf1 is underlined by the remarkable conservation of its sequence from Drosophila to human, with up to 98% identity in between human and rodents. The yeast Paf1 was first described as a component of a complex associated with RNAPII and was believed to contribute to the transcriptional function of this complex. Here, we demonstrate that, similar to yeast Paf1, hPAF1 shows nuclear localization and forms a complex with RNAPII.
RNAPII is the major protein responsible for mRNA synthesis in eukaryotes. It is now known that the initiation, elongation and post-transcriptional regulation of transcription are complex tasks regulated by the interaction between numerous protein complexes, which control the action of RNAPII. The bulk of knowledge about this process is based on investigations carried out in S. cerevisiae. Complete synthesis of mRNA by RNAPII includes at least four distinct steps: (I) recruitment to the promoter and initiation; (II) detachment from the promoter after the formation of the first phosphodiester bond; (III) elongation; and (IV) termination. Paf1 and the PAF1 complex, which includes at least four other members, Rtf1, Cdc73, Leo1, and Ctr9 (for a review, Squazzo et al., 2002; Hampsey and Reinberg, 2003) , are also found at the initiation site. Paf1 docks on the RNAPII phosphorylated carboxyl terminal domain (CTD) and bridges RNAPII with SPT4, SPT5, and SPT16 during the elongation process (Squazzo et al., 2002) . A knockout of Paf1 in yeast causes a severe phenotype that includes a reduced growth rate, and substantially enhanced sensitivity to cytotoxic agents such as 6-azauracil, mycophenolic acid and hydroxyurea (Betz et al., 2002) . This phenotype has been linked, in part, to effects on the transcription of several different genes (Betz et al., 2002) . For example, sensitivity to hydroxyurea in yeast is conferred by specific increases in RNR1 transcript abundance, and sensitivity to 6-azauracil and mycophenolic acid is conferred through the derepression of the IMD2 transcript (Betz et al., 2002) . It is also postulated that generalized post-transcriptional effects on mRNA may also contribute to this phenotype. Evidence exists that there are post-transcriptional functions for Paf1 even when it is uncoupled from RNAPII (Mueller et al., 2004) . In the light of these findings, we propose that the overexpression of hPaf1 in human cells may confer growth advantage or resistance to cytotoxic agents, such as those used in chemotherapy. Thus, hPaf1 may play a central role in the transcription process, contributing to the regulation of expression of specific genes, and to generalized aspects of mRNA stability. In this manner, the overexpression of hPAF1 may substantially contribute to cellular development, differentiation, metabolic control, transformation and drug resistance in normal and tumor cells.
Interestingly, another member of the hPAF1 complex, Cdc73, was recently identified in humans as the product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2 (Woodard et al., 2005) . The authors showed that the transient overexpression of wild-type HRPT2 resulted in cell proliferation inhibition, while its Leu64pro missense mutant detected in parathyroid cancer does not. For this reason, HRPT2 is presented as a tumor suppressor gene (Woodard et al., 2005) . The observation that HRPT2/hCdc73 potentially presents tumor suppressor activity in opposition with the transforming activity of hPAF1 suggests that the hPAF1 complex is crucial in maintaining cellular homeostasis and that its function may be altered by a change in the stoichiometry of the complex or by missense mutation.
In addition to their presence on the same amplicon, hPaf1 and AKT2 share similarities; both are specifically overexpressed in undifferentiated tumor cells and both in vitro and in vivo possess transforming activity. In addition, hPAF1 is a key regulator of transcription, while AKT2 is a key player in the regulation of translation initiation via the FRAP/mTOR pathway (Gingras et al., 2001) . As mentioned previously, amplicons are stabilized when they encompass several genes, especially genes that provide a selective growth advantage to the cancer cells. Specific chromosomal regions are mainly amplified in certain types of tumors and, therefore, may carry genes that facilitate the development of these tumors. The tissue-specific amplification of the 19q13 locus in ovarian, breast, and pancreatic cancers suggests that hPaf1 and AKT2 provide growth advantage and probably increase the aggressiveness of the cancer cells.
In summary, we demonstrated that the human homologue of the RNA polymerase II-associated factor I gene localized within the 19q13 amplicon provides a growth advantage to cancer cells and might act synergistically with the AKT2 oncogene.
Materials and methods
Cell lines
The Panc1 cell line, a poorly differentiated (morphologically and phenotypically) pancreatic adenocarcinoma cell line (Lieber et al., 1975) , was obtained from the American Type Culture Collection (ATCC). The well-differentiated pancreatic tumor cell line, CD11/HPAF, was established at Duke University (Kim et al., 1989) . Cell lines were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum.
Total RNA and DNA purification Total cellular RNA was isolated by the guanidine isothiocyanate-cesium chloride cushion ultracentrifugation method (Chirgwin et al., 1979) . Poly (A) mRNAs were further purified on two cycles of oligo (dT) cellulose affinity chromatography. Genomic DNA from CD11/HPAF and Panc1 cell lines were purified by the SDS-Proteinase K digestion method and then extracted with phenol/chloroform.
Differential screening
The Panc1 cDNA library was subjected to differential hybridization using single-stranded cDNA probes made from mRNA of Panc1 and CD11/HPAF cells. The probes were synthesized using the SuperScripttII Rnase À Reverse
Transcriptase system (Invitrogen, USA), random hexamer primers (Pharmacia, Piscataway, NJ, USA), and 40 mCI a-32 PdCTP. RNA in the cDNA-RNA hybrid was hydrolysed at 651C for 30 min in an equal volume of 0.6 N NaOH and 30 mM EDTA. The specific activity of cDNA obtained was 0.5-1.5 Â 10 8 cpm/mg of RNA. For screening, triplicate nitrocellulose membranes were lifted and subjected to alkaline hydrolysis and neutralization. Prehybridization, hybridization and washing were performed as described previously (Lan et al., 1990; Batra et al., 1991a) . Plaques that hybridized strongly with the Panc1 cDNA probe, but not with the CD11/ HPAF cDNA probe, were selected. The differential reactivity was confirmed through at least two additional screening cycles. Using a DNA insert derived from a differentially expressed cDNA clone, five additional cDNA clones were isolated from a normal human fetal pancreatic cDNA library.
Subcloning and sequence analysis Single phage plaques selected after differential screening were grown to large quantities using either plate lysates or liquid culture followed by glycerol gradient purification (Lan et al., 1990) . Inserts cut with EcoRI from purified DNA were subcloned into pBluescript7vectors (Stratagene, La Jolla, CA, USA). Sequences were determined on both strands by conventional methods and by automated sequencing with an ABI Prism model 377 XL automatic sequencer. Analyses of sequences were performed with the GCG software. The nucleotide sequence reported in this paper was submitted to the EMBL data bank with the accession number, AJ401156. Further analyses were undertaken with PROSITE software at the Expert Protein Analysis System proteomics server of the Swiss Institute of Bioinformation and using the EST and BLAST resources data from the National Center of Biotechnology Information.
Northern and Southern blotting
Total RNAs (20 mg) and/or purified poly(A þ ) RNAs were fractionated by electrophoresis on 1.2% agarose gels containing 0.66 M formaldehyde and transferred onto nitrocellulose via capillary blotting. Genomic DNA were digested with the indicated endonuclease enzymes and separated on 0.8% agarose gel electrophoresis before transfer by capillary action to nylon membranes. The cDNAs were labeled with a 32 Plabeled dCTP using a random-primer labeling kit (Invitrogen). Prehybridization, hybridization, washing, and autoradiography or phosphor-imaging were performed as previously described (Batra et al., 1991b) .
Chromosomal mapping
The chromosomal localization of the PD2 gene was initially performed using the gene-based, sequence-tagged-site (STS) mapping method as published earlier (Berry et al., 1995) . The 3 0 -untranslated region (UT) of the PD2 cDNA sequence was used to design primers for polymerase chain reaction (PCR) screens of both CEPH mega base-insert YAC DNA pools, obtained from Research Genetics, Huntsville, AL, USA (Bellanne-Chantelot et al., 1992) , and Coriell human X rodent somatic cell hybrid DNA pools (Wilcox et al., 1991) . To identify the PD2-specific locus, a walk on the chromosome was performed on the National Center of Biotechnology Information server.
Generation of monoclonal antibody (Mab) against the PD2 protein Female Balb/c mice were immunized (six to seven times) subcutaneously with 50 mg of the 22-residue PD2 peptide, corresponding to amino acids 327-348 (NH 2 -Glu Thr Arg Val Arg Leu Ser Lys Arg Arg Lys Ala Gly Val Gln Ser Gly Thr Asn Ala Leu-COOH), and conjugated to KLH. At 5 days after the final booster, the splenocytes were isolated and fused with SP2/O mouse myeloma cell line, using polyethylene glycol (PEG) as described earlier. Hybridoma secreting PD2-specific antibodies were cloned by limiting dilution. Cells were diluted to three cells/ml and plated (100 ml/well) into 96-well tissue culture plates. After 8 days, clones were screened by an anti-PD2 ELISA, and those yielding the strongest signal were expanded. Female Balb/c mice were given intraperitoneal injections (0.5 ml) of pristane (Sigma) to prime the peritoneum for ascites hybridoma growth. After 7-10 days, primed mice were inoculated with 10 6 cloned hybridoma cells. MAb-rich ascites fluid was harvested after eight to 12 days.
Confocal microscopy Cells (1-5 Â 10 5 cells) were plated on to sterile round coverslip (CIR 18-1 Fisher brand 12-545-10) and grown in 12-well plates. Cells were fixed in acetone/methanol (1:1; prechilled to À201C) and permeabilized in 0.1% Triton X-100 in PBS. Cells were washed in PBS and incubated with primary and secondary antibodies, with washing between incubations. For the blocking experiments, the PD2 antibody was pretreated with 1 mg/ml of PD2-specific peptide, overnight at 41C in a rotator.
Western blot analysis
The protocol for cytoplasmic and nuclear extract preparation was adapted from previously published procedures (Lee and Green, 1990; Meyer et al., 2002) . Cells were allowed to swell on ice for 30 min in hypotonic cytoplasmic extraction buffer (10 mM HEPES, pH 7.4, 10 mM KCl, 0.2% NP-40, 0.1 mM EDTA, 10% glycerol, 1.5 mM MgCl 2 , 1 mM DTT, 1 mM PMSF, 5 mM Na 3 VO 4 , 5mM NaF, supplemented with complete protease inhibitor cocktail (Roche)). Cell disruption was accomplished by several passages through a 25 G needle. Nuclei were collected by centrifugation at 16 000 g, and the supernatant further centrifuged at 16 000 g to yield the final cytoplasmic extract. Nuclear pellets were incubated in hypertonic nuclear extraction buffer (20 mM HEPES (pH 7.6), 420 mM NaCl, 1 mM EDTA, 20% glycerol, 1.5 mM MgCl 2 , 1mM DTT, 1 mM PMSF, 5 mM Na 3 VO 4 , 5 mM NaF, supplemented with complete protease inhibitor cocktail (Roche)). Insoluble materials were precipitated by centrifugation. The supernatant was collected and used as nuclear extract. Total protein extracts were prepared by lysing the cells in RIPA buffer (50 mM Tris-HCl, pH 7.4; 0.25% Na-deoxycholate; 150 mM NaCl; 1% NP-40; 1 mM EDTA), freshly supplemented with 1 mg aprotinin, 1 mg/ml leupeptine, 5 mM NaF, 5 mM Na 3 VO 4 , and 1 mM phenylmethylsulfonyl fluoride (PMSF). Equal amounts of protein (10 mg) were resolved by electrophoresis on 10% laemli SDS-polyacrylamide gels. Fractionated proteins were electrotransferred onto polyvinylidene difluoride (PVDF) membranes, which were blocked in 5% BSA in phosphate-buffered saline (PBS). Blocked membranes were reacted with anti-PD2 mouse monoclonal antibody at 1 mg/ml in PBS containing 0.05% Tween-20 (PBST) overnight at 41C. Membranes were then washed six times (ten minutes each) in PBST and incubated in TBST containing sheep anti-mouse polyclonal antibody conjugated to horseradish peroxidase (1:2000 dilution) for 1 h at room temperature. Following six rinses in PBST, ECL reagents (Amersham, USA) were applied to membranes. For the blocking experiments, the PD2 antibody was preincubated with 0.01, 0.1, and 1 mg/ml of PD2 peptide on a rotator at 41C overnight.
Immunoprecipitations
Immunoprecipitation was performed by adding 5 mg of the appropriate antibodies and negative controls IgG to 100 mg of protein lysates. The reaction mixture was incubated overnight on a rotator at 41C, pulled down with protein G beads, and washed in TBST. Immuno-complexes were eluted from the protein G beads by boiling in 6 Â loading buffer.
Plasmid construction and DNA transfection and tumorigenicity The full-length PD2 cDNA (1.9 kb) was cloned at the EcoRI site in the pCDNA3.1 vector in both the sense and antisense orientation. The NIH3T3 cells were either mock transfected with vector alone or with the PD2-sense and -antisense pCDNA3.1 construct using a procedure described earlier (Singh et al., 2004) . The expression was driven by a strong CMV promoter and the stable transfectants were selected using neomycin selection. The viable NIH3T3 cells (assessed by Trypan blue dye exclusion test) transfected with vector alone and PD2-sense or antisense construct were implanted subcutaneously in the nude mice. The body weight of the animals and the size of the growing tumors were monitored every alternate day. A cell growth curve and the cell doubling time of PD2-mock, PD2-sense, and PD2-antisense transfected cells were established as reported (Singh et al., 2004) . Abbreviations PD2, pancreatic differentiation 2; Paf1, RNA polymerase IIassociated factor; HLH, helix-loop-helix; cAMP, cyclic adenosine monophosphate; kb, kilobase; bp, base pair; PCR, polymerase chain reaction; CGH, comparative genomic hybridization; RRM, eukaryotic RNA recognition motif; RCC1, regulator of chromosome condensation domain; RNAPII, RNA polymerase II; GTFs, general transcription factors.
